Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate | Blood | American Society of Hematology
Kathryn Lurain, Thomas S. Uldrick, Ramya Ramaswami, Mark N. Polizzotto, Priscila H. Goncalves, Anaida Widell, Seth M. Steinberg, Elaine S. Jaffe, Stefania Pittaluga, Hao-Wei Wang, Constance M. Yuan, Mary Anne Tamula, Staci Martin, Pamela L. Wolters, Jomy George, Richard F. Little, Robert Yarchoan; Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood 2020; 136 (19): 2229–2232. doi: https://doi.org/10.1182/blood.2020006048 Download citation file: TO THE EDITOR: HIV-associated primary central nervous system (CNS) lymphoma (HIV-PCNSL), an AIDS-defining malignancy, generally develops in patients with severe CD4+ T-cell lymphopenia. HIV-PCNSL encompasses a variety of CD20+ and usually Epstein Barr virus (EBV)–positive B-cell lymphoproliferative disorders, with a range of polymorphic and monomorphic morphologies.1-3 The World Health Organization classification also recognizes a form of primary diffuse large B-cell lymphoma
Explore this link on the map →